Evidence status · reviewed 1 August 2026
One dated view of the VK2735 evidence base, keeping the subcutaneous and oral formulations separate — the peer-reviewed subcutaneous VENTURE Phase 2, the oral VENTURE topline, and the pending Phase 3 VANQUISH trials. Evidence state comes before headline magnitude.
VK2735 remains investigational and is not approved; its Phase 3 VANQUISH program is ongoing. This tracker is research context, not clinical or personal-use guidance.
The statuses below describe the source available for each result, not an approval status or a judgment about clinical use.
Adults with obesity or overweight · Phase 2 · 13 weeks · subcutaneous, weekly
Published in Obesity, once-weekly subcutaneous VK2735 produced mean body-weight reductions of up to 14.7% (up to 13.1% placebo-adjusted) at week 13, meeting all endpoints, with up to 88% of treated patients losing at least 10% versus 4% with placebo (n=176, NCT06068946).
Adults with obesity or overweight · Phase 2 · 13 weeks · oral, daily
In company data presented at ECO 2026, once-daily oral VK2735 produced dose-dependent mean body-weight reductions of up to 12.2% at week 13, with up to 80% of participants losing at least 10% and up to 97% at least 5%, versus 5% and 10% with placebo. A peer-reviewed publication was not identified at this tracker’s review (n=280, NCT06828055).
Obesity without type 2 diabetes · Phase 3 · 78 weeks · subcutaneous
The registrational subcutaneous Phase 3 trial is fully enrolled (about 4,500) with an estimated primary completion in 2027. Detailed results were not identified as released at this tracker’s review (NCT07104500).
Obesity with type 2 diabetes · Phase 3 · 78 weeks · subcutaneous
The registrational subcutaneous Phase 3 trial in type 2 diabetes completed enrollment (about 1,000) in early 2026, with an estimated primary completion in 2027. Detailed results were not identified as released at this tracker’s review (NCT07104383).
How to read this tracker
A full report has passed journal review and exposes methods and analyses for scrutiny.
A primary-source company release is available, but the complete paper may not yet be published.
The registry establishes design and status; it does not substitute for a results publication.
See where VK2735 sits in the wider incretin pipeline, then check the sister approval tracker on Remy Peptides.